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ORTHOTOPIC LIVER TRANSPLANTATION IN HIGH-RISK 
PATIENTS 
RISK FACTORS AsSOCIATED WITH MORTALITY AND INFECTIOUS MORBIDITY 
TIMOTHY GAYOWSKI,1 IGNAZIO R. MARINo, NINA SINGH, HOWARD DOYLE, MARILYN WAGENER, 
JOHN J. FUNG, AND THOMAS E. STARZL 
Thomas E. Starzl TranspLantation Institute, University of Pittsburgh Medical Center, and the Department of Medicine, 
Veterans Administration Medical Center. Pittsburgh, Pennsylvania 
Background. One of the most controversial areas in 
patient selection and donor allocation is the high-risk 
patient. Risk factors for mortality and major infec-
tious morbidity were prospectively analyzed in con-
secutive United States veterans undergoing liver 
transplantation under primary tacrolimus·based im-
munosuppression. 
Methods. Twenty-eight pre-liver transplant, opera-
tive, and posttransplant risk factors were examined 
univariately and multivariately in 140 consecutive 
liver transplants in 130 veterans (98% male; mean age, 
47.3 years). 
Results. Eighty-two percent of the patients had post-
necrotic cirrhosis due to viral hepatitis or ethanol 
(20% ethanol alone), and only 12% had cholestatic liver 
disease. Ninety-eight percent of the patients were hos-
pitalized at the time of transplantation (66% United 
Network for Organ Sharing [UNOS] 2,32% UNOS 1). 
Major bacterial infection, posttransplant dialysis, ad-
ditional immunosuppression, readmission to intensive 
care unit (P=O.OOOI for alD, major fungal infection, 
I Address correspondence to: Timothy Gayowski, M.D., Thomas E. 
StaTZI Transplantation Institute, 4th Floor. Falk Clinic. 3601 Fifth 
Avenue, Pittsburgh, PA 15213. 
posttransplant abdominal surgery, posttransplant in-
tensive care unit stay length of stay (P<O.005 for alD, 
donor age, pre transplant dialysis, and creatinine 
. (P<0.05 for all) were significantly associated with 
mortality by univariate analysis. Underlying liver dis-
ease, cytomegalovirus infection and disease, portal 
vein thrombosis, UNOS status, Childs-Pugh score, pa-
tient age, pretransplant bilirubin, ischemia time, and 
operative blood loss were not significant predictors of 
mortality. Patients with hepatitis C (HCV) and recur· 
rent HCV had a trend towards higher mortality 
(P=0.18). By multivariate analysis, donor age, any ma-
jor infection, additional immunosuppression, post· 
transplant dialysis, and subsequent transplantation 
were significant independent predictors of mortality 
(P<0.05). Major infectious morbidity was associated 
with HCV recurrence (P=O.003), posttransplant dialy-
sis (P=O.OOOl), pretransplant creatinine, donor age, 
median blood loss, intensive care unit length of stay, 
additional immunosuppression, and biopsy-proven re-
jection (P<0.05 for alD. By multivariate analysis, 
intensive care unit length of stay and additional im· 
munosuppression were significant independent pre-
dictors of infectious morbidity (P<0.03). HCV recur-
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rence was of borderline significance (P=O.07). 
Conclusions. Biologic and physiologic parameters 
appear to be more powerful predictors of mortality and 
morbidity after liver transplantation. Both donor and 
recipient variables need to be considered for early and 
late outcome analysis and risk assessment modeling. 
The number of cadaveric organ donors in the United States 
has remained relatively static while the candidate waiting 
list for solid organ transplants has grown exponentially (1). 
This growing disparity in supply and demand has catalyzed 
much debate regarding current allocation policies with views 
ranging from the utilitarian to the deontologic (2-4). One 
potential solution is readily evident in that the current po-
tential pool of cadaver organs can probably meet the needs of 
those who are in the greatest need. Unfortunately, the aver-
age number of solid organ donors actually realized from this 
potential pool is less than one half (5, 6). Until this is recti-
fied, the transplant community is faced with difficult selec-
tion and allocation decisions. Both the scarcity of donor or-
gans and economic considerations have promulgated a 
number of investigators to examine preoperative, intra-oper-
ative, and postoperative risk factors in an effort to better 
predict outcome (7-12). Analyses have included both donor 
and recipient characteristics; however, a fully developed risk 
assessment model has not yet been realized. 
One of the most controversial areas in patient selection 
and donor allocation is the high-risk patient (2). Several 
reports have concluded that transplantation of these patients 
is ill-advised, given the current economic climate and the 
current donor/recipient disparity (3, 4). This utilitarian 
stance has been challenged with several authors reporting 
acceptable outcomes including quality of life (2, 13-16). 
Under primary tacrolimus (Prograf, formerly FK506)-
based immunosuppression, we have had the opportunity to 
examine a unique high-risk group of consecutive United 
States veterans undergoing orthotopic liver transplantation. 
We analyzed a number of preoperative, intra-operative, and 
postoperative risk factors for both mortality and major infec-
tious morbidity in an effort to better define predictors of 
outcome in the high-risk patient group. 
PATIENTS AND METHODS 
Between October 1989 and October 1995, 140 liver transplants 
were performed in 130 consecutive United States veterans under 
primary tacrolimus-based immunosuppression at the Veterans Ad-
ministration Medical Center in Pittsburgh (one patient had a com-
bined liverlkidney transplant). There were 128 (98%) males and 2 
(2%) females with a mean age of 47.3 years (range, 22-70 years). 
There were 15 patients (11.5%) over the age of 60 (all male). The 
mean follow-up for survivors was 50:t21.6 months (range, 15-88 
months). The etiology of underlying liver disease is shown in Table 1. 
Pretransplant patient characteristics and morbidity are shown in 
Table 2. The immunosuppressive regimen has been described previ-
ously (17) with lower doses of induction tacrolimus and routine use of 
intravenous prostaglandin E-1 over the past 4 years. 
Risk Factors Examined 
Recipients. Pretransplant variables included age, diagnosis (in-
cluding fulminant hepatic failure and hepatoma), United Network 
for Organ Sharing (UNOS*) status, need for mechanical ventilation, 
* Abbreviations: HCV, hepatits C virus; ICU, intensive care unit; 
UNOS, United Network for Organ Sharing. 
TABLE l. Indications for primary liver transplantation in United 
States veterans under primary tacrolimus (FK506. Prograf) 
immunosuppression° 
n (%) 
Viral hepatitis 
Hepatitis C 68 (53) 
Hepatitis B 12 (9) 
Alcoholic cirrhosisb 58 (45) 
Cholestatic disease 
PBC 2 (2) 
PSC 13 (10) 
Metabolic disease 5 (4) 
Cryptogenic cirrhosis 7 (4) 
Hepatocellular carcinoma" 12 (9) 
Polycystic liver _1 (1) 
Total 130 
a Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; 
PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis. 
b Of the patients with alcohol-related disease, 29 had associated 
HCV, 32 had HCV and HBV, and 1 had HBV. 
C Associated liver diseases included hepatitis B (2 patients), alco-
holic cirrhosis (3 patients), cryptogenic cirrhosis (3 patients), hepa-
titis C (3 patients), and Wilson's disease (1 patient). 
TABLE 2. Patient demographics and pretransplant risk factorsO 
Age (mean) (range, 22-69 yr) 47.3 
Sex 
Male 
Female 
Childs-Pugh score (mean) (range, 6-15) 
UNOS status 
3 
2 
1 
Bilirubin (mean mg/dl) 
Renal function 
Creatinine (mean mg/dl) 
Creatinine 2:2.0 
Dialysis 
Pre-OLTx antibioticsb 
Portal vein thrombosis 
98% 
2% 
11.5 
2% 
66% 
32% 
5.86 
1.43 
16% 
4% 
28% 
23% 
a Abbreviations: OLTx, orthotopic liver transplant; UNOS, United 
Network for Organ Sharing. 
b Antibiotic use within 4 weeks of OLTx. 
Childs-Pugh score, serum bilirubin, serum creatinine, need for he-
modialysis, antibiotic therapy required within 4 weeks of transplant, 
weight >100 kg, multi-organ transplantation, and complications of 
portal hypertension. 
Donor and intraoperative factors. Donor age, gender, ischemia 
time (time from cross-clamping to reperfusion), intra-operative blood 
loss, and recipient portal vein thrombosis were examined. 
Posttransplant factors. These included length of intensive care 
unit (lCU) stay, need for ICU readmission, posttransplant surgery 
(abdominal), antibiotic therapy during the first 4 weeks, need for 
dialysis, subsequent transplantation, incidence of rejection and re-
quirement for additional immunosuppression (steroid bolus, recycle, 
or OKT3), cytomegalovirus infection and disease, major bacterial 
and fungal infections (18), and hepatitis C recurrence. 
Statistical Analysis 
Clinical and laboratory data were entered into a data base (Proph-
et Statistics, BBN Systems and Technologies, Cambridge, MA). Cat-
egorized variably (mortality. infection) were compared using the 
• 
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FIGURE 1. Kaplan-Meier patient and graft survival curves. 
chi-square test or the Fisher exact test. Ordinal values such as 
UNOS or Childs-Pugh were compared using the Mann-Whitney U 
test. Kaplan-Meier probability survival curves were constructed us-
ing the date of first transplant as the starting point and loss of graft 
or death as the endpoints. Survival curves were compared using the 
Mantel-Cox log-rank test. 
RESULTS 
The underlying liver disease and demographic character-
istics of the patients are reported in Tables 1 and 2. The 
overall actuarial patient survival rates were 90%, 87%, 85%, 
and 80% at 6, 12, 24, and 60 months, respectively (Fig. 1). 
Graft survival was 86%, 83%, 76%, and 70% at 6, 12, 24, and 
60, months respectively. Ten patients (8%) received addi-
tional transplants, including 1 patient who received three 
grafts, with a long-term actuarial survival rate of 50%. 
Risk Factors for Mortality 
Univariate analysis. Patient mortality was associated 
with need for subsequent transplantation (22% vs. 4.7%, 
P=0.016), major bacterial (70% vs. 26%, P=O.OOOl) and fun-
gal infections (30% vs. 6.6%, P=0.003), pre- and posttrans-
plant dialysis (48% vs. 8.5%, P=O.OOOl), pretransplant cre-
atinine (2.0 mg/dl vs. 1.3 mg/dl, P=0.04), donor age (40.5 
years vs. 31.4 years, P=O.Ol), posttransplant abdominal sur-
gery (43% vs. 18%, P=0.0005), requirement for augmented 
immunosuppression, number of rejection episodes (1.3 vs. 
0.4, P=0.009),length of post transplant leu stay (25 days vs. 
7.1 days, P=0.004), and readmission to leu (52% vs. 25%, 
P=O.OOOl) (Table 3). 
Underlying liver disease, need for mechanical ventilation, 
cytomegalovirus infection and disease, portal vein thrombo-
sis, UNOS status, Childs-Pugh score, patient age, pretrans-
plant bilirubin, donor sex, ischemia time, and operative blood 
loss and complications of portal hypertension were not sig-
nificant predictors of mortality (Table 4). Several factors 
analyzed did not have sufficient numbers to define statistical 
significance. These include patient weight> 100 kg (n=9), 
fulminant hepatic failure (n=O), multi-organ transplantation 
(n= 1), and hepatoma (n=12). It is notable that patients with 
TABLE 3. Risk factors associated with mortality: 
univariate analysisa 
Risk factor Dead Alive p (n=23) (n=106) 
Pre-OLTx 
Need for dialysis 13% 6.6% 0.04 
Serum creatinine (mean) 2.0 1.3 0.04 
Donor age (mean) 40.5 31.4 0.01 
Post-OLTx 
Need for dialysis 48% 8.5% 0.0001 
Surgery (abdomina)) 43% 18o/c 0.0005 
Augmented 78% 33% 0.0001 
Immunosuppression 
No. of steroid boluses (mean) 1.7 0.4 0.001 
No. of steroid re-cycles (mean) 0.65 0.19 0.01 
Biopsy-proven rejection (mean no.) 1.3 0.4 0.009 
Major infections 
Bacterial 70% 26% 0.0001 
Fungal 30% 6.6% 0.003 
ICU LOS (mean no. of days) 25 7.1 0.004 
Readmission to ICU 52% 25% 0.0001 
Subsequent transplantation 22% 4.7% 0.016 
a Abbreviations: ICU, intensive care unit; LOS, length of stay; 
OLTx, orthotopic liver transplant. 
TABLE 4. Risk factors not associated with mortality" 
Risk factor Dead Alive (n=23) (n=106) 
Liver diseaseb (%) 
Hepatitis (viral) 
C 65 50 
B 13 84 
Ethanol 43 45 
Cholestatic (PSCIPBC) 4 13 
Metabolic 0 5 
Cryptogenic 9 5 
Hepatoma 13 8 
Portal vein thrombosis 30 22 
UNOS status (%) 
3 0 3 
2 70 65 
1 30 32 
Childs-Pugh score (mean) 11.9 11.4 
Patient age (mean) 45.7 45.7 
Donor sex (%) 
Male 78 76 
Female 22 24 
Pre-OLTx Female bilirubin (mean mg/dl) 4.9 6.0 
Ischemia time (mean hr :!: sm 12.7:t4 13.5:t3 
Operative blood loss (no. of PRBCs) 15 12.5 
a Abbreviations: OLTx, orthotopic liver transplant; PBC, primary 
biliary cirrhosis; pRBC, packed red blood cells; PSC, primary scle-
rosing cholangitis; UNOS, United Network for Organ Sharing. 
b Some patients have more than one underlying disease. 
HCV had higher mortality (P=O.18) as did patients with 
posttransplant HeV recurrence (P=0.185), although statis-
tical significance was not achieved. 
Multivariate analysis. Variables found to be significant in 
the univariate analysis were utilized for stepwise logistic 
regression analysis. Donor age (P=0.04), any major infection 
(P=O.02), additional immunosuppression (P=O.Ol), post-
transplant dialysis (P=0.006), posttransplant surgery, biop-
sy-proven rejection. and need for subsequent transplantation 
,. 
~J i 
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(P=0.02) were identified as significant independent predic-
tors of mortality (Table 5l. 
Risk Factors for Infectious Morbidity 
Univariate analysis. Donor age, recipient pretransplant 
creatinine, need for mechanical ventilation, need for post-
transplant dialysis, operative blood loss, ICU length of stay, 
biopsy-proven rejection, augmented immunosuppression, 
and HCV recurrence were associated with increased major 
infectious morbidity (Table 6). 
Multivariate analysis. By multivariate analysis, ICU 
length of stay, and additional immunosuppression were sig-
nificant independent predictors of infectious morbidity 
(P<0.03) for all variables. HCV recurrence was of borderline 
significance (P=0.07) (Table 7). 
Subsequent Transplantation 
Overall, 10 patients underwent retransplantation. Subse-
quent transplantation occurred within 2 weeks of the original 
transplant in seven patients (median = 5 days). Recipient por-
tal vein thrombosis (P=O.Ol) and median blood loss (25 units 
of packed red blood cells vs. 12 units of packed red blood cells, 
P=0.004) were statistically significant factors for subsequent 
transplantation. Requirements for subsequent transplanta-
tion in patients with portal vein thrombosis were not associ-
ated with problems of portal in-flow or other vascular com-
plications. 
DISCUSSION 
Orthotopic liver transplantation was originally conceived 
and developed for patients with end-stage liver disease who 
had little hope for survival otherwise. Refinements in surgi-
cal technique, immunosuppression, and peri-operative man-
agement had expanded the indications for transplantation. 
As a result, the number of candidates for liver transplanta-
tion has grown rapidly, while the organ pool has remained 
relatively stagnant. This supply and demand disparity has 
led to much controversy regarding organ allocation (2, 3, 4, 
15). Many have argued that liver transplantation should be 
performed in patients who are less ill, citing better survival 
rates and lesser costs (3, 4). A recent report from the Univer-
sity of Wisconsin showed no significant difference in long-
term survival with UNOS status 4 patients (old classifica-
tion) (11). This is consistent with our observations in this 
select group of veteran patients. We and others have found 
that these desperately ill patients can be treated with accept-
able 1- and 3-year survival rates with the most dramatic gain 
in life-years compared with the low-risk patient (15). Recent 
data on patient outcome and graft survival have suggested 
that UNOS status is a somewhat artificial classification and 
TABLE 5. Risk factors associated with mortality: 
multivariate analysis" 
Risk factor 
Donor age 
Post-OLTx dialysis 
Augmented immunosuppression 
Major infection 
Subsequent transplant 
Odds ratio (95% cn p 
1.04 
S.065 
5.91 
S.15 
9.54 
(0.5-6.9) 0.04 
(1.9-39.9) 0.006 
(1.4-24.6) 0.01 
0.5-45.1) 0.02 
(1.4-63.5) 0.02 
° Abbreviations: cr, confidence interval; OLTx, orthotopic liver 
transplant. 
TABLE 6. Risk factors for infectious morbidity: univariate analysisO 
Risk factor. Infection No infection p In=58' (n=71) 
Pre-OLTx 
Donor age lmean) 36 30.5 0.03 
Serum creatinine (mean) 1.7 1.2 0.04 
Operative 
Blood loss (median no. of pRBCs ) 15.5 10 0.02 
Post-OLTx 
Need for mechanical ventilation 69% 2S'H 0.003 
Need for dialysis 29% 4.2'if 0.0001 
ICU LOS (mean no. of days) 15.3 6.1 0.001 
No. of steroid boluses (mean) 1.0 0.2 0.001 
No. of steroid recycles (mean) 0.4 0.1 0.015 
Biopsy-proven rejection (mean no.) O.S 0.3 0.001 
HCV recurrence 36% 14% 0.003 
" Abbreviations: HCV, hepatitis C virus; ICU, intensive care unit; 
LOS, length of stay; OLTx, orthotopic liver transplant. 
TABLE 7. Risk factors for infectious morbidity: 
multivariate analysis" 
Risk factors Odds ratio 
ICU length of stay 
Augmented immunosuppression 
HCV recurrence 
LOS 
3.18 
2.57 
(95% Cll P 
(1.0-1.16) 0.03 
(1.3-7.83) 0.01 
(0.93-7.09) 0.07 
a Abbreviations: CI, confidence interval; HCV, hepatitis C virus; 
ICU, intensive care unit. 
physiologic variables appear to be more powerful predictors 
of outcome (7, 10, 12, 19). We would suggest that the high-
risk patient group (currently designated as UNOS 1 and 2, or 
hospitalized patients) needs to be defined more precisely to 
aid the transplant physician to better decide which high-risk 
patients can be salvaged with reasonable outcome. How shall 
we further define the high-risk patient? The Blue Cross/Blue 
Shield consortium have classified high-risk recipients accord-
ing to diagnosis, prior operative procedures and patient con-
dition (20). Several of these risk factors such as portal vein 
thrombosis and previous right upper quadrant surgery have 
not, however, been shown to result in significantly poorer 
survival rates (16). Other physiologic parameters have been 
shown to be better predictors of outcome for early and late 
(greater than 6 months) outcome (7, 18). 
Severity of liver dysfunction as reflected by degree of hy-
perbilirubinemia and coagulopathy have been shown to be 
significant predictors of mortality in patients requiring ICU 
care for end-stage liver disease (7, 10, 19). An analysis of a 
series of patients in the University of Wisconsin era has 
indicated that requirement for mechanical ventilation and 
elevated bilirubin are significant independent predictors of 
graft failure (19). Eckhoff et a1. (13) found that prolonged 
partial thromboplastin time was a significant independent 
risk factor for mortality in UNOS 4 patients. Advanced dis-
ease as evident by requirement for ICU support (UNOS 4) 
and Childs class C have also been associated with higher 
mortality. We did not find these factors to be predictive of 
mortality or infectious morbidity. However, this is likely a 
result of the skewed nature of our patient population; the 
mean Childs-Pugh score of our patients was 11.5, 70% were 
Childs class C and the vast majority (98%) were hospitalized 
at the time of transplantation. Graft dysfunction requiring 
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retransplantation was a significant independent predictor of 
patient mortality, and this is consistent with the literature 
(7,9, 11, 19). 
Renal insufficiency has been implicated as a harbinger of 
not only mortality, but increased infectious morbidity in both 
patients waiting for transplantation, as well as those under-
going transplantation (10, 12). A recent report examined the 
impact of renal insufficiency (defined as creatinine >1.6 mg/ 
dl> on outcome (21). A lower patient and graft survival was 
noted in patients presenting with fulminant hepatic failure. 
Renal insufficiency did not, however, affect patient survival 
in patients with cirrhosis, except in those requiring dialysis 
or combined liver-kidney transplants. Other notable obser-
vations were longer hospital and ICU length of stay, adding 
to overall costs of transplantation in these patients. Our 
results differ in that not only patients requiring dialysis but 
all patients with renal insufficiency had a significantly 
higher mortality. In addition, Brown et a1. (21) did not ex-
amine the impact of renal insufficiency on infectious morbid-
ity and a multivariate analysis was not performed. We agree 
with the approach of Baliga et a1. (10) that instituting ag-
gressive volume support and assessment with invasive mon-
itoring in an attempt to reverse any prerenal component, as 
well as other studies to rule out hepatorenal syndrome or 
glomerulonephropathies is indicated. Although we concur 
with the conclusions of Baliga et al., it is important to note 
that they only assessed hospital mortality and their criteria 
for infections were not as rigorous as those used in our report. 
From our data, renal insufficiency both before and after 
transplantation would appear to have farther reaching con-
sequences in terms of mortality and infectious morbidity. 
Ideally, intervention with liver transplantation is desired 
before progression to full renal support. 
Donor age was a significant independent predictor of mor-
tality in our patient population. This is consistent with ob-
servations in a much larger series of patients examining 
graft failure defined as patient death or retransplantation (7, 
19). Conversely, donor sex and ischemia time did not impact 
significantly on mortality or infectious morbidity, and this is 
likely due to our much smaller number of observations in this 
group of hospitalized patients. This serves to illustrate again 
that we must be cognizant of donor, as well as recipient 
factors when attempting to predict outcome or likelihood of 
success. 
Our observation of increased mortality in patients requir-
ing augmented immunosuppression is neither surprising nor 
unique (22-24). It is also not surprising that patients expe-
riencing a major infection or requiring posttransplant ab-
dominal surgery are at higher risk for mortality. These oc-
currences are not predictable preoperatively, and do not add 
to our ability to predict outcomes in the high-risk patient. 
These observations do, however, serve to illustrate that im-
munosuppression should be administered judiciously and 
technical imperfections are not tolerated well by the recipi-
ent. 
Augmented immunosuppression and ICU length of stay 
were significant predictors of infectious morbidity. Major in-
fections are not unexpected sequelae associated with these 
risk factors. Recurrent HCV hepatitis also appears to impact 
adversely upon infectious morbidity. HCV is thought to have 
immunomodulatory properties and perhaps recurrent HCV 
may facilitate infections from pathogens associated with de-
pressed cell-mediated immunity (25, 26). 
In conclusion. biologic and physiologic parameters appear 
to be better predictors of mortality and morbidity after liver 
transplantation. More subjective and artificial categoriza-
tions such as UNOS status were not important factors in our 
patient population. This is perhaps explained by the skewed 
nature of our high-risk patient group; nearly all patients 
required hospitalization at the time of transplantation. Our 
data indicate that donor age and renal failure (with or with-
out the need for dialysis) are markers for mortality and 
infectious morbidity. It is notable that in spite of this risk 
profile, the overall patient survival is excellent and adds 
further testimony to the salvageability of high-risk patients 
in need of liver transplantation. These observations merit 
further investigation in a larger series of high-risk patients 
to realize a more accurate risk assessment model to optimize 
the allocation of a presently scarce resource. 
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